Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Histogenics Corporation to Present at the 2016 Cell & Gene Meeting on the Mesa

Posted on: 26 Sep 16

WALTHAM, Mass., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, President and Chief Executive Officer of Histogenics, will be presenting a corporate overview during the meeting’s Partnering Forum on Wednesday, October 5, 2016, at 5:15 pm PDT. The conference will be held October 5-7 at the Estancia La Jolla Hotel & Spa in La Jolla California and will feature a two-day Partnering Forum, a Public Forum lecture and a full-day Scientific Symposium. The Cell & Gene Meeting on the Mesa is organized by the Alliance for Regenerative Medicine (ARM) and the Sanford Consortium for Regenerative Medicine.

This presentation will be webcast live and may be accessed by visiting the Investor Relations section of Histogenics’ website at or at and will also be published on ARM’s website shortly after the event. The webcast will be archived and available on Histogenics’ website for 45 days following the conference.

About Histogenics Corporation

Histogenics is a leading regenerative medicine company developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions to treat musculoskeletal-related conditions. Histogenics’ first investigational product candidate, NeoCart®, is currently in Phase 3 clinical development. NeoCart is an autologous cell therapy designed to treat cartilage defects in the knee using the patient’s own cells. Knee cartilage defects represent a significant opportunity in the United States, with an estimated 500,000 or more applicable procedures each year. NeoCart is designed to exhibit characteristics of articular, hyaline cartilage prior to and upon implantation into the knee and therefore does not rely on the body to make new cartilage, characteristics not exhibited in other current treatment options. For more information, please visit


Last updated on: 27/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.